Abbott Laboratories (ABT)
NYSE: ABT · Real-Time Price · USD
127.19
-0.92 (-0.72%)
At close: Nov 24, 2025, 4:00 PM EST
127.26
+0.07 (0.06%)
After-hours: Nov 24, 2025, 7:32 PM EST
Abbott Laboratories Revenue
Abbott Laboratories had revenue of $11.37B in the quarter ending September 30, 2025, with 6.90% growth. This brings the company's revenue in the last twelve months to $43.84B, up 6.37% year-over-year. In the year 2024, Abbott Laboratories had annual revenue of $41.95B with 4.59% growth.
Revenue (ttm)
$43.84B
Revenue Growth
+6.37%
P/S Ratio
5.05
Revenue / Employee
$384,588
Employees
114,000
Market Cap
221.17B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 41.95B | 1.84B | 4.59% |
| Dec 31, 2023 | 40.11B | -3.54B | -8.12% |
| Dec 31, 2022 | 43.65B | 578.00M | 1.34% |
| Dec 31, 2021 | 43.08B | 8.47B | 24.47% |
| Dec 31, 2020 | 34.61B | 2.70B | 8.48% |
| Dec 31, 2019 | 31.90B | 1.33B | 4.34% |
| Dec 31, 2018 | 30.58B | 3.19B | 11.64% |
| Dec 31, 2017 | 27.39B | 6.54B | 31.35% |
| Dec 31, 2016 | 20.85B | 448.00M | 2.20% |
| Dec 31, 2015 | 20.41B | 158.00M | 0.78% |
| Dec 31, 2014 | 20.25B | 590.00M | 3.00% |
| Dec 31, 2013 | 19.66B | 607.00M | 3.19% |
| Dec 31, 2012 | 19.05B | -2.36B | -11.01% |
| Dec 31, 2011 | 21.41B | -13.76B | -39.13% |
| Dec 31, 2010 | 35.17B | 4.40B | 14.31% |
| Dec 31, 2009 | 30.76B | 1.24B | 4.19% |
| Dec 31, 2008 | 29.53B | 3.61B | 13.94% |
| Dec 31, 2007 | 25.91B | 3.44B | 15.30% |
| Dec 31, 2006 | 22.48B | 138.51M | 0.62% |
| Dec 31, 2005 | 22.34B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
ABT News
- 15 hours ago - Abbott issues US device correction for some glucose monitors over faulty readings risk - Reuters
- 3 days ago - Exact Sciences Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Exact Sciences Corporation - EXAS - Business Wire
- 4 days ago - Abbott's $21 Billion Exact Sciences Buyout Reshapes Cancer Diagnostics - Benzinga
- 4 days ago - Why Abbott is paying $21 billion for Exact Sciences and its Cologuard cancer test - Market Watch
- 4 days ago - Abbott to Acquire Exact Sciences for $21 Billion - WSJ
- 4 days ago - Exact Sciences Stock Soars. Abbott Is Buying It in Deal Valued at $21 Billion. - Barrons
- 4 days ago - Abbott bolsters diagnostics portfolio with up to $23 billion buyout of Exact Sciences - Reuters
- 4 days ago - Abbott to acquire Exact Sciences, a leader in large and fast-growing cancer screening and precision oncology diagnostics segments - PRNewsWire